Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

Three Coagulation Related Mutations and Increased Risk of Myoma in Women of Fars Province

Razieh Moghtaderi Nasab 1 , Mahboobeh Nasiri 1 , * and Ahmad Ebrahimi 2
Authors Information
1 Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, IR Iran
2 Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: October 2016, 18 (10); e4002
  • Published Online: September 28, 2016
  • Article Type: Research Article
  • Received: September 4, 2015
  • Revised: October 19, 2015
  • Accepted: September 24, 2016
  • DOI: 10.17795/zjrms-4002

To Cite: Moghtaderi Nasab R, Nasiri M, Ebrahimi A. Three Coagulation Related Mutations and Increased Risk of Myoma in Women of Fars Province, Zahedan J Res Med Sci. 2016 ; 18(10):e4002. doi: 10.17795/zjrms-4002.

Abstract
Copyright © 2016, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Duhan N. Current and emerging treatments for uterine myoma - an update. Int J Womens Health. 2011; 3: 231-41[DOI][PubMed]
  • 2. Terry KL, Tworoger SS, Goode EL, Gates MA, Titus-Ernstoff L, Kelemen LE, et al. MTHFR polymorphisms in relation to ovarian cancer risk. Gynecol Oncol. 2010; 119(2): 319-24[DOI][PubMed]
  • 3. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007; 87(4): 725-36[DOI][PubMed]
  • 4. Ruf W, Schaffner F. Role of the protein C receptor in cancer progression. Thromb Res. 2014; 133 Suppl 2: 85-9[DOI][PubMed]
  • 5. Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res. 2009; 148: 31-41[DOI][PubMed]
  • 6. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23(10): 2130-5[DOI][PubMed]
  • 7. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2(8): 1266-71[DOI][PubMed]
  • 8. Singh A, Pandey S, Pandey LK, Saxena AK. In human alleles specific variation of MTHFR C677T and A1298C associated "risk factor" for the development of ovarian cancer. J Exp Ther Oncol. 2015; 11(1): 67-70[PubMed]
  • 9. Miri-Moghaddam E, Saravani S, Garme Y, Khosravi A, Bazi A, Motazedian J. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms in oral squamous cell carcinoma in south-east Iran. J Oral Pathol Med. 2016; 45(2): 96-100[DOI][PubMed]
  • 10. Ghasemi S, Tavakoli A, Moghadam M, Zargar MA, Abbaspour M, Hatamnejadian N, et al. Risk of prostate cancer and thrombosis-related factor polymorphisms. Biomed Rep. 2014; 2(1): 53-6[DOI][PubMed]
  • 11. Dennis J, Johnson CY, Adediran AS, de Andrade M, Heit JA, Morange PE, et al. The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. Blood. 2012; 119(10): 2392-400[DOI][PubMed]
  • 12. Nishikawa H, Ideishi M, Nishimura T, Kawamura A, Kamochi H, Tahara H, et al. Deep venous thrombosis and pulmonary thromboembolism associated with a huge uterine myoma--a case report. Angiology. 2000; 51(2): 161-6[PubMed]
  • 13. Wu HC, Chang CH, Tsai RY, Lin CH, Wang RF, Tsai CW, et al. Significant association of methylenetetrahydrofolate reductase single nucleotide polymorphisms with prostate cancer susceptibility in taiwan. Anticancer Res. 2010; 30(9): 3573-7[PubMed]
  • 14. Ericson U, Sonestedt E, Ivarsson MI, Gullberg B, Carlson J, Olsson H, et al. Folate intake, methylenetetrahydrofolate reductase polymorphisms, and breast cancer risk in women from the Malmo Diet and Cancer cohort. Cancer Epidemiol Biomarkers Prev. 2009; 18(4): 1101-10[DOI][PubMed]
  • 15. Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sorensen JB, et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009; 20(10): 1660-6[DOI][PubMed]
  • 16. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992; 12: 279-98[DOI][PubMed]
  • 17. Varga EA, Sturm AC, Misita CP, Moll S. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation. 2005; 111(19): 289-93[DOI][PubMed]
  • 18. Haynes MC, Lu BY, Winkel AF. Ovarian vein thrombophlebitis related to large uterine myoma. Obstet Gynecol. 2014; 123(2 Pt 2 Suppl 2): 450-3[DOI][PubMed]
  • 19. Roberts-Thomson IC, Butler WJ. Polymorphism and gastric cancer. J Gastroenterol Hepatol. 2005; 20(5): 793-4[DOI][PubMed]
  • 20. Levine AJ, Figueiredo JC, Lee W, Poynter JN, Conti D, Duggan DJ, et al. Genetic variability in the MTHFR gene and colorectal cancer risk using the colorectal cancer family registry. Cancer Epidemiol Biomarkers Prev. 2010; 19(1): 89-100[DOI][PubMed]
  • 21. Mari D, Ogliari G, Castaldi D, Vitale G, Bollini EM, Lio D. Hemostasis and ageing. Immun Ageing. 2008; 5: 12[DOI][PubMed]
  • 22. Uitte de Willige S, Van Marion V, Rosendaal FR, Vos HL, de Visser MC, Bertina RM. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost. 2004; 2(8): 1305-10[DOI][PubMed]
  • 23. Qu D, Wang Y, Song Y, Esmon NL, Esmon CT. The Ser219-->Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype. J Thromb Haemost. 2006; 4(1): 229-35[DOI][PubMed]
  • 24. Castellino FJ, Ploplis VA. The protein C pathway and pathologic processes. J Thromb Haemost. 2009; 7 Suppl 1: 140-5[DOI][PubMed]
  • 25. Menschikowski M, Hagelgans A, Eisenhofer G, Siegert G. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Exp Cell Res. 2009; 315(15): 2673-82[DOI][PubMed]
  • 26. Anastasiou G, Politou M, Rallidis L, Grouzi E, Karakitsos P, Merkouri E, et al. Endothelial Protein C Receptor Gene Variants and Risk of Thrombosis. Clin Appl Thromb Hemost. 2016; 22(2): 199-204[DOI][PubMed]
  • 27. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem. 1997; 43(9): 1678-83[PubMed]
  • 28. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8(6): 513-8[PubMed]
  • 29. Crott JW, Mashiyama ST, Ames BN, Fenech MF. Methylenetetrahydrofolate reductase C677T polymorphism does not alter folic acid deficiency-induced uracil incorporation into primary human lymphocyte DNA in vitro. Carcinogenesis. 2001; 22(7): 1019-25[PubMed]
  • 30. Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, et al. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat. 2007; 104(3): 299-308[DOI][PubMed]
  • 31. Sharp L, Little J, Schofield AC, Pavlidou E, Cotton SC, Miedzybrodzka Z. Folate and breast cancer: The role of polymorphisms in methylenetetra hydrofolate reductase (MTHFR). Cancer Lett. 2002; 18(1): 65-71[DOI]
  • 32. Rai PS, Pai GC, Alvares JF, Bellampalli R, Gopinath PM, Satyamoorthy K. Intraindividual somatic variations in MTHFR gene polymorphisms in relation to colon cancer. Pharmacogenomics. 2014; 15(3): 349-59[DOI][PubMed]
  • 33. Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin Y, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. Int J Cancer. 2001; 95(5): 332-6[PubMed]
  • 34. Shen H, Spitz MR, Wang LE, Hong WK, Wei Q. Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 2001; 10(4): 397-401[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments